Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1)

Journal of Pharmacology and Experimental Therapeutics

Volumn 334, Issue 3, 2010, Pages 936-944

  Lai, Yurong ^a   Sampson, Kathleen E ^a   Balogh, Larissa M ^a   Brayman, Timothy G ^a   Cox, Steven R ^b   Adams, Wade J ^c   Kumar, Vikas ^a   Stevens, Jeffrey C ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b ZOETIS   (United States)

^c ADaMET Consulting LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CIMETIDINE; GLYCOPROTEIN P; MEMBRANE PROTEIN; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 2; N [[3 [4 (1,1 DIOXIDOTHIOMORPHOLIN 4 YL) 3,5 DIFLUOROPHENYL] 2 OXO 1,3 OXAZOLIDIN 5 YL]METHYL]ACETAMIDE; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; ORGANIC CATION TRANSPORTER 2; OXAZOLIDINONE DERIVATIVE; PLACEBO; PNU 288034; PROBENECID; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; MATE1 PROTEIN, HUMAN; N-((3-(4-(1,1-DIOXIDOTHIOMORPHOLIN-4-YL)-3,5-DIFLUOROPHENYL)-2-OXO-1,3-OXAZOLIDIN-5-YL)METHYL)ACETAMIDE; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; SULFOXIDE; URINARY TRACT AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; DRUG TRANSPORT; EXPERIMENTAL DOG; EXPERIMENTAL MONKEY; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; KIDNEY TUBULE EXCRETION; LIVER MICROSOME; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; ACTIVE TRANSPORT; ADULT; ANIMAL; CACO 2 CELL LINE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG INTERACTION; FEMALE; INTESTINE ABSORPTION; KIDNEY; KNOCKOUT MOUSE; MACACA FASCICULARIS; MALE; METABOLISM; RANDOMIZED CONTROLLED TRIAL; RAT; SPRAGUE DAWLEY RAT;

ADULT; ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; CACO-2 CELLS; CIMETIDINE; CYCLIC S-OXIDES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; INTESTINAL ABSORPTION; KIDNEY; MACACA FASCICULARIS; MALE; MICE; MICE, KNOCKOUT; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; ORGANIC CATION TRANSPORT PROTEINS; OXAZOLIDINONES; PROBENECID; RATS; RATS, SPRAGUE-DAWLEY; RENAL AGENTS;

EID: 77956235037     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.170753     Document Type: Article

References (40)

1. Abel S, Nichols DJ, Brearley CJ, and Eve MD (2000) Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide. Br J Clin Pharmacol 49:64-71.
2. Arnold EK and Beasley VR (1989) The pharmacokinetics of chlorinated phenoxy acid herbicides: a literature review. Vet Hum Toxicol 31:121-125.
3. Buist SC and Klaassen CD (2004) Rat and mouse differences in gender-predominant expression of organic anion transporter (Oat1-3; Slc22a6-8) mRNA levels. Drug Metab Dispos 32:620-625.
4. Chu XY, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, Xu S, Bergman AJ, Braun MP, Dean DC, et al. (2007) Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther 321:673-683.
5. Dedrick R, Bischoff KB, and Zaharko DS (1970) Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep 54:95-101.
6. Deeley RG, Westlake C, and Cole SP (2006) Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 86:849-899.
7. Dresser MJ, Leabman MK, and Giacomini KM (2001) Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J Pharm Sci 90:397-421.
8. El-Sheikh AA, Masereeuw R, and Russel FG (2008) Mechanisms of renal anionic drug transport. Eur J Pharmacol 585:245-255.
9. Feng B, Obach RS, Burstein AH, Clark DJ, de Morais SM, and Faessel HM (2008) Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study. Clin Pharmacol Ther 83:567-576.
10. Gorzinski SJ, Kociba RJ, Campbell RA, Smith FA, Nolan RJ, and Eisenbrandt DL (1987) Acute, pharmacokinetic, and subchronic toxicological studies of 2,4-dichlorophenoxyacetic acid. Fundam Appl Toxicol 9:423-435.
11. Hosoyamada M, Sekine T, Kanai Y, and Endou H (1999) Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol Renal Physiol 276:F122-F128. (Pubitemid 29061732)
12. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, and Endou H (2004) Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci 94:197-202.
13. Koh WJ, Kwon OJ, Gwak H, Chung JW, Cho SN, Kim WS, and Shim TS (2009) Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 64:388-391.
14. Lai Y, Xing L, Poda GI, and Hu Y (2007) Structure-activity relationships for interaction with multidrug resistance protein 2 (ABCC2/MRP2): the role of torsion angle for a series of biphenyl-substituted heterocycles. Drug Metab Dispos 35:937-945.
15. Lee W and Kim RB (2004) Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol 44:137-166.
16. Lentz KA, Polli JW, Wring SA, Humphreys JE, and Polli JE (2000) Influence of passive permeability on apparent P-glycoprotein kinetics. Pharmacol Res 17:1456-1460.
17. Li M, Anderson GD, and Wang J (2006) Drug-drug interactions involving membrane transporters in the human kidney. Expert Opin Drug Metab Toxicol 2:505-532.
18. Mahmood I (1998) Interspecies scaling of renally secreted drugs. Life Sci 63:2365-2371.
19. Matsushima S, Maeda K, Inoue K, Ohta KY, Yuasa H, Kondo T, Nakayama H, Horita S, Kusuhara H, and Sugiyama Y (2009) The inhibition of human multidrug and toxin extrusion 1 is involved in the drug-drug interaction caused by cimetidine. Drug Metab Dispos 37:555-559.
20. Motohashi H, Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M, Fukatsu A, Ogawa O, and Inui K (2002) Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol 13:866-874.
21. Motohashi H, Uwai Y, Hiramoto K, Okuda M, and Inui K (2004) Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol 503:25-30.
22. Ohta KY, Imamura Y, Okudaira N, Atsumi R, Inoue K, and Yuasa H (2009) Functional characterization of multidrug and toxin extrusion protein 1 as a facilitative transporter for fluoroquinolones. J Pharmacol Exp Ther 328:628-634.
23. Omote H, Hiasa M, Matsumoto T, Otsuka M, and Moriyama Y (2006) The MATE proteins as fundamental transporters of metabolic and xenobiotic organic cations. Trends Pharmacol Sci 27:587-593.
24. 14C]linezolid to healthy human subjects. Drug Metab Dispos 29:1136-1145.
25. Somogyi A, McLean A, and Heinzow B (1983) Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. Eur J Clin Pharmacol 25:339-345.
26. Somogyi A, Stockley C, Keal J, Rolan P, and Bochner F (1987) Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 23:545-551.
27. Sweet DH (2005) Organic anion transporter (Slc22a) family members as mediators of toxicity. Toxicol Appl Pharmacol 204:198-215.
28. Tahara H, Kusuhara H, Chida M, Fuse E, and Sugiyama Y (2006a) Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J Pharmacol Exp Ther 316:1187-1194.
29. Tahara H, Kusuhara H, Maeda K, Koepsell H, Fuse E, and Sugiyama Y (2006b) Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid. Drug Metab Dispos 34:743-747.
30. Tahara H, Shono M, Kusuhara H, Kinoshita H, Fuse E, Takadate A, Otagiri M, and Sugiyama Y (2005) Molecular cloning and functional analyses of OAT1 and OAT3 from cynomolgus monkey kidney. Pharmacol Res 22:647-660.
31. +-organic cation antiporters. Biochem Pharmacol 74:359-371.
32. +/organic cation antiporter MATE1. Pharmacol Res 23:1696-1701.
33. Tsuda M, Terada T, Ueba M, Sato T, Masuda S, Katsura T, and Inui K (2009) Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther 329:185-191.
34. Uwai Y, Saito H, and Inui K (2000) Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. Eur J Pharmacol 409:31-36.
35. van Crugten J, Bochner F, Keal J, and Somogyi A (1986) Selectivity of the cimetidine- induced alterations in the renal handling of organic substrates in humans. Studies with anionic, cationic and zwitterionic drugs. J Pharmacol Exp Ther 236:481-487.
36. Wright SH and Dantzler WH (2004) Molecular and cellular physiology of renal organic cation and anion transport. Physiol Rev 84:987-1049.
37. Xiao Y, Davidson R, Smith A, Pereira D, Zhao S, Soglia J, Gebhard D, de Morais S, and Duignan DB (2006) A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line. Mol Pharm 3:45-54.
38. Yasui-Furukori N, Uno T, Sugawara K, and Tateishi T (2005) Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther 77:17-23.
39. Yuan H, Feng B, Yu Y, Chupka J, Zheng JY, Heath TG, and Bond BR (2009) Renal organic anion transporter-mediated drug-drug interaction between gemcabene and quinapril. J Pharmacol Exp Ther 330:191-197.
40. Zaher H, zu Schwabedissen HE, Tirona RG, Cox ML, Obert LA, Agrawal N, Palandra J, Stock JL, Kim RB, and Ware JA (2008) Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol 74:320-329.